| Contributors: |
Pecorelli, A.; Lenzi, B.; Gramenzi, A.; Garuti, F.; Farinati, F.; Giannini, E. G.; Ciccarese, F.; Piscaglia, F.; Rapaccini, G. L.; Di Marco, M.; Caturelli, E.; Zoli, M.; Borzio, F.; Sacco, R.; Cabibbo, G.; Felder, M.; Morisco, F.; Gasbarrini, A.; Baroni, G. S.; Foschi, F. G.; Biasini, E.; Masotto, A.; Virdone, R.; Bernardi, M.; Trevisani, F.; Bolondi, L.; Biselli, M.; Bucci, L.; Caraceni, P.; Cucchetti, A.; Domenicali, M.; Magalotti, D.; Serra, C.; Venerandi, L.; Giacomin, A.; Maddalo, G.; Pozzan, C.; Vani, V.; Poggio, P. D.; Olmi, S.; Balsamo, C.; Vavassori, E.; Benvegnu, L.; Cappelli, A.; Golfieri, R.; Mosconi, C.; Renzulli, M.; Bosco, G.; Roselli, P.; Dell'Isola, S.; Ialungo, A. M.; Bruzzone, L.; Picciotto, A.; Marenco, S.; Risso, D.; Sammito, G.; Savarino, V.; Camma, C.; Maida, M.; Costantino, A.; Barcellona, M. R.; Affronti, A.; Mega, A.; Rinninella, E.; Mismas, V.; Cappa, F. M.; Dall'Aglio, A. C.; Feletti, V.; Lanzi, A.; Neri, E.; Stefanini, G. F.; Tamberi, S.; Missale, G.; Porro, E.; Guarino, M.; Gemini, S.; Schiada, L. |
| Description: |
Background & Aims: The Barcelona Clinic Liver Cancer intermediate stage (BCLC-B) of hepatocellular carcinoma (HCC) includes extremely heterogeneous patients in terms of tumour burden and liver function. Transarterial-chemoembolization (TACE) is the first-line treatment for these patients although it may be risky/useless for someone, while others could undergo curative treatments. This study assesses the treatment type performed in a large cohort of BCLC-B patients and its outcome. Methods: Retrospective analysis of 485 consecutive BCLC-B patients from the ITA.LI.CA database diagnosed with naïve HCC after 1999. Patients were stratified by treatment. Results: 29 patients (6%) were lost to follow-up before receiving treatment. Treatment distribution was: TACE (233, 51.1%), curative treatments (145 patients, 31.8%), sorafenib (18, 3.9%), other (39, 8.5%), best supportive care (BSC) (21, 4.6%). Median survival (95% CI) was 45months (37.4–52.7) for curative treatments, 30 (24.7–35.3) for TACE, 14 (10.5–17.5) for sorafenib, 14 (5.2–22.7) for other treatments and 10 (6.0–14.2) for BSC (P |